Core Viewpoint - The company reported significant growth in its packaging and printing business in the first half of the year, while the cosmetics segment's revenue share did not increase further, and gross margins remained stable [1] Group 1: Business Performance - The packaging and printing business experienced substantial year-on-year revenue growth [1] - The cosmetics business's contribution to total revenue did not see further improvement [1] - Gross margin levels were maintained without significant fluctuations [1] Group 2: Strategic Initiatives - The company is enhancing its cosmetics OEM business by executing a defined business development strategy and focusing on building strategic partnerships with key clients, particularly ODM customers [1] - A rolling forecast system and real-time order shipment monitoring system were established to improve business precision and service quality [1] Group 3: Product Development - The company has identified key product development strategies based on market research and competitive analysis, focusing on skincare, wax-based, and powder categories [1] - New flagship products such as water light cream, multi-use potato mud cream, and blush cream were successfully developed [1] Group 4: Operational Strategy - The company's main operational focus is on the principles of "increasing revenue" and "cost-saving" to achieve continuous business expansion and profit improvement [1]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [12]. Core Insights - The company achieved a revenue of 515 million yuan in H1 2025, representing a year-on-year growth of 43.76%, and a net profit attributable to shareholders of 78.32 million yuan, up 432.14% year-on-year [1]. - The packaging segment generated 479 million yuan in revenue, a 52.85% increase year-on-year, driven by market expansion and significant growth in the packaging printing business [2]. - The cosmetics segment reported a revenue of 42.29 million yuan, down 13.52% year-on-year [2]. - The company has signed strategic cooperation agreements with several new clients, including major cosmetics and health companies, and has successfully developed new products in its subsidiaries [2]. Financial Summary - The company's gross margin improved to 28.40% in H1 2025, an increase of 7.37 percentage points year-on-year [3]. - Revenue projections for 2025-2027 are estimated at 1.117 billion yuan, 1.426 billion yuan, and 1.769 billion yuan, respectively, with net profits expected to be 152 million yuan, 204 million yuan, and 267 million yuan [3][4]. - The report indicates a significant increase in earnings per share, projected to rise from 0.31 yuan in 2024 to 0.88 yuan in 2027 [4]. Market Data - As of September 4, 2025, the company's closing price was 17.63 yuan, with a 12-month price range of 13.28 to 37.43 yuan [5]. - The total market capitalization is approximately 5.33 billion yuan [5]. Performance Metrics - The company has shown strong absolute returns of 80% over the past 12 months, outperforming the market [8]. - The projected price-to-earnings ratio is expected to decrease from 83.39 in 2024 to 19.97 in 2027, indicating improved valuation over time [4].